Catalyst Brief

← Calendar

Readoutin 103d

Ionis Pharmaceuticals, Inc. — Olezarsen

Phase 3 primary completion: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG).

Date
Mar 2027
Type
Readout
Indication
Severe Hypertriglyceridemia

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.